stockrowErasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Return on invested capital
Erasca, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −203.1%, down 23.8 percentage points from fiscal 2025 (−179.4%). Over the past ten years it has ranged from −2,040.0% (fiscal 2023) to 0.00% (fiscal 2022); the current reading is higher than 43% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −179.4% | (89.71) |
| FY2024 | −89.7% | 1,950.31 |
| FY2023 | −2,040.0% | (2,039.97) |
| FY2022 | 0.00% | 185.60 |
| FY2021 | −185.6% | (185.60) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| COGT Cogent Biosciences, Inc. compare | 0.00% |
| CRSP CRISPR Therapeutics AG compare | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| DFTX Definium Therapeutics, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −9.54% |
| DNTH Dianthus Therapeutics, Inc. compare | −36.6% |
| TVTX Travere Therapeutics, Inc. compare | −54.1% |
| ERAS Erasca, Inc. | −203.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)